Journal of the National Cancer Institute
regelmäßige Einnahmen von Aspirin ist offenbar in der Lage,
die Häufigkeit des Vorkommens von Bauchspeicheldrüsen-Krebs
(Pankreas Karzinom) deutlich zu vermindern.
Journal of the National Cancer Institute, Vol. 94, No. 15, 1168-1171,
August 7, 2002
Oxford University Press
Association Between Nonsteroidal Anti-Inflammatory Drug Use and
the Incidence of Pancreatic Cancer
Kristin E. Anderson, Trista W. Johnson,
DeAnn Lazovich, Aaron R. Folsom
Affiliation of authors: Division of Epidemiology, School of
Public Health, University of Minnesota, Minneapolis.
Correspondence to: Kristin E. Anderson, Ph.D., Division of
Epidemiology, University of Minnesota, 1300 S. Second St., #300,
Minneapolis, MN 55454 (e-mail: email@example.com).
Laboratory studies indicate that nonsteroidal anti-inflammatory
drugs (NSAIDs) may inhibit pancreatic cancer, but epidemiologic
data to support this finding are limited. We conducted a
prospective study from 1992 through 1999 among 28 283
postmenopausal women who lived in Iowa to examine the
association between the self-reported use of aspirin
and other NSAIDs and the incidence of pancreatic cancer.
Eighty incident cases of pancreatic cancer were identified
during 7 years of follow-up.
The multivariate-adjusted relative risk of pancreatic
cancer associated with any current use of aspirin versus
no use was 0.57 (95% confidence interval = 0.36 to
0.90). There was a trend of decreasing risk of pancreatic
cancer incidence with increasing frequency of aspirin use
per week (Ptrend = .005). Nonaspirin
NSAID use was not associated with incident pancreatic
cancer. These data indicate that aspirin might be chemopreventive
for pancreatic cancer.
This article has been cited by other articles: